Sign Out
Click on icon to see table/diagram/imagePatients with mantle cell lymphoma: The safety profile of Bortezomib in these patients with mantle cell lymphoma was similar to that observed in patients with multiple myeloma. Notable differences between the two patient populations were that thrombocytopenia, neutropenia, anemia, nausea, vomiting and pyrexia were reported more often in the patients with multiple myeloma than in those with mantle cell lymphoma; whereas peripheral neuropathy, rash and pruritus were higher among patients with mantle cell lymphoma compared to patients with multiple myeloma.
View ADR Reporting Link
Lanjutkan dengan Google